LU82345A1 - Methode de detection du cancer - Google Patents

Methode de detection du cancer Download PDF

Info

Publication number
LU82345A1
LU82345A1 LU82345A LU82345A LU82345A1 LU 82345 A1 LU82345 A1 LU 82345A1 LU 82345 A LU82345 A LU 82345A LU 82345 A LU82345 A LU 82345A LU 82345 A1 LU82345 A1 LU 82345A1
Authority
LU
Luxembourg
Prior art keywords
cancer
concentration
dna
protein
bleomycin
Prior art date
Application number
LU82345A
Other languages
English (en)
French (fr)
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of LU82345A1 publication Critical patent/LU82345A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Sink And Installation For Waste Water (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
LU82345A 1979-04-10 1980-04-08 Methode de detection du cancer LU82345A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2873279A 1979-04-10 1979-04-10
US2873279 1979-04-10

Publications (1)

Publication Number Publication Date
LU82345A1 true LU82345A1 (fr) 1980-12-16

Family

ID=21845111

Family Applications (1)

Application Number Title Priority Date Filing Date
LU82345A LU82345A1 (fr) 1979-04-10 1980-04-08 Methode de detection du cancer

Country Status (24)

Country Link
JP (1) JPS55143441A (de)
KR (1) KR830002502A (de)
AR (1) AR222700A1 (de)
AT (1) AT365343B (de)
AU (1) AU536522B2 (de)
BE (1) BE882669A (de)
CH (1) CH644453A5 (de)
DE (1) DE3013837A1 (de)
DK (1) DK149980A (de)
ES (1) ES490396A0 (de)
FI (1) FI801078A7 (de)
FR (1) FR2454099A1 (de)
GB (1) GB2047712B (de)
GR (1) GR67692B (de)
HU (1) HU183122B (de)
IE (1) IE49981B1 (de)
IL (1) IL59772A (de)
IT (1) IT1143135B (de)
LU (1) LU82345A1 (de)
NL (1) NL8002094A (de)
NO (1) NO801018L (de)
PH (1) PH15637A (de)
SE (1) SE8002602L (de)
ZA (1) ZA802141B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524644A1 (de) * 1985-07-10 1987-01-15 Heyl Chem Pharm Undulin und dessen peptidfragmente, verfahren zu deren herstellung und ihre verwendung

Also Published As

Publication number Publication date
FR2454099A1 (fr) 1980-11-07
BE882669A (fr) 1980-10-06
IL59772A0 (en) 1980-06-30
ES8103380A1 (es) 1981-02-16
AU536522B2 (en) 1984-05-10
GR67692B (de) 1981-09-07
HU183122B (en) 1984-04-28
KR830002502A (ko) 1983-05-30
JPS55143441A (en) 1980-11-08
IE49981B1 (en) 1986-01-22
ATA195780A (de) 1981-05-15
CH644453A5 (fr) 1984-07-31
ES490396A0 (es) 1981-02-16
IL59772A (en) 1983-05-15
SE8002602L (sv) 1980-12-09
GB2047712A (en) 1980-12-03
IE800693L (en) 1980-10-10
IT1143135B (it) 1986-10-22
AU5719380A (en) 1980-10-16
IT8048370A0 (it) 1980-04-09
FR2454099B1 (de) 1984-01-27
FI801078A7 (fi) 1981-01-01
AR222700A1 (es) 1981-06-15
AT365343B (de) 1982-01-11
ZA802141B (en) 1981-04-29
NO801018L (no) 1980-10-13
PH15637A (en) 1983-03-11
GB2047712B (en) 1983-02-23
NL8002094A (nl) 1980-10-14
DK149980A (da) 1980-10-11
DE3013837A1 (de) 1980-10-30

Similar Documents

Publication Publication Date Title
Vinceti et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite
ES2346467T3 (es) Marcadores neurodegenerativos para la depresion.
FR2461256A1 (fr) Procede et necessaire de diagnostic du cancer par determination des liaisons glucosidiques associees aux tumeurs
WO2010012306A1 (en) Healthy kidney biomarkers
JP2012524883A (ja) 腎臓障害生物マーカとしてのｗｎｔ１
Zhang et al. Glycemic variability is associated with vascular calcification by the markers of endoplasmic reticulum stress-related apoptosis, Wnt1, galectin-3 and BMP-2
Arfvidsson et al. S100B concentrations increase perioperatively in jugular vein blood despite limited metabolic and inflammatory response to clinically uneventful carotid endarterectomy
JP7589323B2 (ja) 猫の腎機能障害の検査方法
Motomiya et al. Circulating level of α2-macroglobulin–β2-microglobulin complex in hemodialysis patients
Hamad et al. Assessment the role of kidney function and total proteins in patients with diabetic nephropathy in Kirkuk city/Iraq
Schwartz et al. Quantitative assay of erythrocyte “free” and zinc-protoporphyrin: Clinical and genetic studies
de Jong et al. Sample collection and handling considerations for peptidomic studies in whole saliva; implications for biomarker discovery
CA1129321A (en) Diagnostic method
Xiang et al. Simultaneous determination of serum tryptophan metabolites in patients with systemic lupus erythematosus by high performance liquid chromatography with fluorescence detection.
CH644453A5 (fr) Methode de detection du cancer.
KR102475926B1 (ko) 전신 홍반성 루푸스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루푸스 진단에 필요한 정보를 제공하는 방법
KR102608933B1 (ko) 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
Tulley et al. Method for the simultaneous determination of cadmium and zinc in whole blood by atomic absorption spectrophotometry and measurement in normotensive and hypertensive humans
Kȩdziora‐Kornatowska et al. Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension
Ecke et al. Development of point-of-care tests for urinary bladder cancer–an historic review and view to future prospectives
KR102497196B1 (ko) 전립선암 진단 점수 계산 방법 및 그 용도
EP4703729A1 (de) Verfahren zur bestimmung von iga-nephropathie
US5804368A (en) Method for screening for prostate cancer by measuring apolipoprotein D levels in body fluid
WO2023143650A1 (en) Method for determination of mutated form of mucin-1 protein in a biological sample
Wang et al. Development and Evaluation of an LC-MS/MS Method for Determining Paraquat and Diquat in Human Plasma: a Retrospective Study.